![]() ![]() Some lawsuits have also claimed punitive damages to punish the drug maker financially. Additionally, treatments and recovery from adverse events like severe bleeding often require taking time off work, resulting in lost wages for many patients.Įliquis lawsuits have been filed to recover compensatory damages like lost wages and medical expenses attributed to complications of the drug. In some cases, not all of these treatments are covered by insurance. ![]() The medical costs to treat serious bleeding can accumulate quickly between emergency room visits and follow-up appointments. However, many of the patients taking Eliquis who experienced complications from the drug experienced significant financial losses. In 2016 alone, Eliquis made $3.3 billion in sales for Bristol-Myers Squibb. Newer blood thinners like Eliquis, Xarelto, and Pradaxa have been incredibly profitable for drug manufacturers in recent years. The majority of the lawsuits filed against the drug makers stem from patients injuries reported prior to the antidote's release when Eliquis could be especially dangerous to patients should they sustain an injury. Following the approval of the reversal agent Andexaa in May 2018, Eliquis and Xarelto both became significantly safer drugs for patient use. How an Eliquis Antidote Affects Legal ClaimsĪll blood thinners pose some risk to patients, but for the first six years that Eliquis was on the market, the drug had no antidote, rendering many severe bleeding events in patients irreversible. Ultimately, the FDA went through with the approval after determining that the misconduct did not affect the trial results. The FDA delayed the drug's approval process twice for a total of nine months while the agency investigated allegations of trial misconduct at the Chinese clinical testing sites. Clinical Trial Data Scrutinizedĭespite published study data highlighting the blood thinner's promising benefits, Eliquis did not have a smooth road to gain approval from the U.S. Many of these patients and their family members have filed Eliquis bleeding lawsuits against Bristol-Myers Squibb and Pfizer for failing to sufficiently warn patients of the drug's grave side effects. In the time between the drug's release and the antidote's approval, multiple patients taking Eliquis suffered severe, uncontrollable, and in some cases, fatal bleeding events. It wasn't until 2018, that the antidote Andexaa was approved for both Eliquis and Xarelto. Eliquis entered the market with no approved antidote available. However, at the time of its release in 2012, Eliquis had one major disadvantage to traditional blood thinners. The clinical study found that Eliquis prevented 21% more strokes than warfarin and showed a reduced risk of bleeding incidents for patients over an average time of 1.8 years. Even before its approval, the benefits of Eliquis versus more traditional blood thinners like warfarin were touted by cardiologists following the release of clinical trial data for the drug. Like Xarelto, Eliquis is a factor Xa inhibitor anticoagulant, a newer class of blood thinners that has been praised for improved ease of use. Why People Filed Eliquis Lawsuits?Įliquis is an oral anticoagulant prescribed to reduce the risk of blood clots and strokes in patients with atrial fibrillation. People filing these lawsuits claim that the manufacturer Bristol-Myers Squibb and the drug's co-marketer Pfizer did not adequately warn patients and physicians of the drug's bleeding risks. Boarding & Prep School Sexual Abuse LawsuitĪuthored by: Katy Moncivais, Ph.D., Medical EditorĮliquis lawsuits revolve around the blood thinner's serious and sometimes fatal side effect of bleeding. ![]()
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |